​

Avenue Therapeutics Stock (NASDAQ:ATXI)

OwnershipFinancialsChart
Avenue Therapeutics by TradingView

Previous Close

$0.26

52W Range

$0.25 - $10.43

50D Avg

$0.83

200D Avg

$1.93

Market Cap

$787.74K

Avg Vol (3M)

$416.08K

Beta

0.10

Div Yield

-

ATXI Company Profile

Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

2

IPO Date

Jun 27, 2017

Website

ATXI Performance

ATXI Financial Summary

Dec 24Dec 23Dec 22
Revenue---
Operating Income$-11.28M$-14.54M$-8.04M
Net Income$-11.65M$-10.38M$2.05M
EBITDA$-11.28M$4.05M-
Basic EPS$-0.90$-73.60$0.94
Diluted EPS$-0.90$-73.48$0.94

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

TickerCompany
HOTHHoth Therapeutics, Inc.
BDRXBiodexa Pharmaceuticals Plc
WINTWindtree Therapeutics, Inc.
CNSPCNS Pharmaceuticals, Inc.
ALLRAllarity Therapeutics, Inc.
VRAXVirax Biolabs Group Limited
REVBRevelation Biosciences, Inc.
QNRXQuoin Pharmaceuticals, Ltd.
PALIPalisade Bio, Inc.